[Lys]3[Lys]11-VmCT1-NH2

General Information


DRACP ID  DRACP02282

Peptide Name   [Lys]3[Lys]11-VmCT1-NH2

Sequence  FLKALWNVAKKVF

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma 12.5 µM MTT assay 24 h 1

Hemolytic Activity  Human erythrocytes: ~0% Hemolytic=3.1 µM

Normal (non-cancerous) Cytotoxicity  MCF-10A: Not active up to 25 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02282

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C79H122N18O15

Absent amino acids  CDEGHIMPQRSTY

Common amino acids  K

Mass  177818

Pl  11.1

Basic residues  3

Acidic residues  0

Hydrophobic residues  9

Net charge  3

Boman Index  654

Hydrophobicity  70

Aliphatic Index  120

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  458.33

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 31181304

Title  The effect of lysine substitutions in the biological activities of the scorpion venom peptide VmCT1

Doi 10.1016/j.ejps.2019.06.006

Year  2019

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_16792

DRACP is developed by Dr.Zheng's team.